Villers-lès-Nancy, France, 21 September 2015 - 18:00 (CET)
PRESS RELEASE
Net profit up 7% in H1 2015
| € millions | H1 2015 | H1 2014 | Change |
| Turnover (1 January to 30 June) | 56.19 | 58.31 | (3.6%)* |
| Operating profit | 14.04 | 13.32 | + 5.4% |
| Net profit | 9.29 | 8.68 | + 7.0% |
| Net profit attributable to equity holders of the parent | 9.26 | 8.72 | + 6.2% |
| Basic earnings per share (in €) | 3.09 | 2.87 | + 7.7% |
*Restated for Communication Services, sales rose 4.5%
The Board of Directors of PHARMAGEST INTERACTIVE reviewed and approved the accounts for H1 2015 during its meeting on 11 September 2015, chaired by Thierry Chapusot. The statutory auditors performed an interim review of the half-year consolidated financial statements.
- H1 profit up
Having fully wound down the low-margin Communication Services, turnover for the PHARMAGEST Group declined 3.6% in H1 2015 compared with the same period in 2014. Restated for the discontinued business, turnover rose 4.5%. The Group's Divisions delivered steady growth: the Solutions for Pharmacy Division - Europe rose 0.7%, the Solutions for sanitary and medico-social establishments Division was up 11.3%, while growth for the Solutions for e-Health Division was up 158.3%.
Operating profit rose 5.4% to €14.4 million, reflecting a favorable product mix and a rigorous management policy.
Net profit came in at €9.29 million (7% growth) and Net profit attributable to equity holders of the parent climbed 6.2% year-on-year.
As at 30 June 2015, basic earnings per share amounted to €3.09 (up from €2.87 at 30 June 2014).
- Consolidated balance sheet - key data
The PHARMAGEST Group's cash position improved with available liquidity of €52.35 million at 30 June 2015, up from €47.2 million at end-H1 2014.
Equity capital was €82 million at 30 June 2015.
- Selected financial information for H1 2015
- A new equipment leasing subsidiary was established in January 2015. NANCEO is now part of the FINTECH Division and represents a new area of expertise for PHARMAGEST. NANCEO has already taken over sales financing for PHARMAGEST INTERACTIVE;
- PHARMAGEST INTERACTIVE scooped first prize in the Business France Silver Economy Awards held in Paris on 24 June last for its innovative line-up of solutions to improve treatment compliance, and particularly for the DO-Pill SecuR(TM) pill dispenser;
- The Lorraine Regional Council (Conseil Régional de Lorraine) and the European Regional Development Fund (ERDF) agreed to grant a total subsidy of €1.5 million to support the Group's project to extend the length of time people can be cared for at home ("36 mois de plus à domicile");
- PHARMAGEST INTERACTIVE was granted the TECH 40 label launched by EnterNext on 27 April and is now one of the new label's BioTech / MedTech young technology stocks;
- PHARMAGEST INTERACTIVE joined the new ENTERNEXT TECH 40 European stock market index;
- 5-for-1 stock split and new ISIN code for PHARMAGEST shares: FR0012882389.
-
- H2 2015 Outlook
- Our long-established business and the backbone of the PHARMAGEST Group, the Solutions for Pharmacy Division - Europe will continue to create synergies between the businesses and subsidiaries to guarantee profitable and sustainable value.
- The Group's strategy of positioning itself as a key player in connected health devices is beginning to show results. The Solutions for e-Health Division has started to make a significant contribution to the PHARMAGEST Group's turnover, a trend we expect to consolidate in H2.
- The PHARMAGEST Group will continue to keep a close eye out for acquisition opportunities in innovative health-related technologies.
Financial calendar:
- Interim results presentation meeting on 22 September 2015, Paris
- MidCap Event on 7 and 8 October 2015, Paris
- Q3 turnover published on 12 November 2015
About the PHARMAGEST Group:
The PHARMAGEST Group is the French leader in pharmacy information technology, with a 43.5% share of the market and over 800 employees. The strategy of the PHARMAGEST Group is based on a core business - innovating in information technology to improve healthcare - and on the development of two priority focuses: services and technologies for healthcare professionals, notably support for pharmacists in monitoring patient compliance; and technology for improving the efficacy of healthcare systems.
To roll out that strategy, the PHARMAGEST Group has developed specialised businesses, including pharmacy IT, e-Health solutions, solutions for healthcare professionals, solutions for laboratories, connected health devices and apps, and a sales financing marketplace.
These businesses are divided into 4 Divisions: the Solutions for Pharmacy Division - Europe, the Solutions for Sanitary and Medico-Social Establishments Division, the Solutions for e-Health Division, and the FinTech Division.
Listed on Euronext Paris(TM) - Compartment B
Indices: ENTERNEXT TECH 40, CAC ® SMALL and CAC ® All-Tradable by inclusion
Eligible for the Long-Only Deferred Settlement Service (SRD)
ISIN: FR0012882389 - Reuters: PHA.PA - Bloomberg: PMGI FP
PHARMAGEST shares are eligible for France's Equity Savings Plan intended to finance SMEs (PEA-PME)
For all the latest news, go to www.pharmagest.com
CONTACTS
Chairman of the Board:
Thierry CHAPUSOT
Chief Executive Officer:
Dominique PAUTRAT
Tel. +33(0)3 83 15 90 67 - dominique.pautrat@pharmagest.com
Analyst and Investor Relations:
Chief Administrative and Financial Officer: Jean-Yves SAMSON
Tel. +33(0)3 83 15 90 67 - jean-yves.samson@pharmagest.com
Press Relations:
FIN'EXTENSO - Isabelle APRILE
Tel. +33 (0)1 39 97 61 22 - i.aprile@finextenso.fr
